Dr. Matthew H. Carabasi MD Medical Oncologist

Dr. Matthew Carabasi is a medical oncologist in Philadelphia, Pennsylvania. He is affiliated with multiple hospitals in the area, including Lankenau Medical Center and Thomas Jefferson University Hospital. He received his medical degree from Jefferson Medical College and has been in practice for 34 years. Dr. Carabasi accepts several types of health insurance, listed below. He is one of 15 doctors at Lankenau Medical Center and one of 19 at Thomas Jefferson University Hospital who specialize in Medical Oncology.

Are you Dr. Matthew Carabasi? Claim your profile to make edits or add details. Edit Profile

Office Location

See Contact Information

Specialty & Clinical Interests

Medical Oncologist: Hematologic

Clinical Interests: Bone Marrow Transplantation, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease

Hospital Affiliation

Lankenau Medical Center
High performing in Cancer

Thomas Jefferson University Hospital
Ranked #17 in Cancer

Education & Medical Training

Drexel University/Hahnemann University Hospital
Residency, Internal Medicine, 1980 - 1983

Memorial Sloan-Kettering Cancer Center
Fellowship, Medical Oncology, 1985 - 1989

Jefferson Medical College
Class of 1980

Certifications & Licensure

American Board of Pediatrics
Certified 21 years in Pediatrics

American Board of Pediatrics
Certified 8 years in Developmental-Behavioral Pediatrics

AZ State Medical License
Active through 2014

Awards, Honors & Recognition

Meaningful Use Stage 1 Certification, Centers for Medicare & Medicaid Services

Publications & Presentations

Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?
Horan, J.T., Logan, B.R., Agovi-Johnson, M., Lazarus, H.M., Bacigalupo, A.A., Ballen, K.K., Bredeson, C.N., Carabasi, M.H., Gupta, V., Hale, G.A., Khoury, H.J., Juckett, M.B., Litzow, M.R., Martino, R., McCarthy, P.L., Smith, F.O., Rizzo, J.D., Pasquini

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.
Lee, S.J., Kukreja, M., Wang, T., Giralt, S.A., Szer, J., Arora, M., Woolfrey, A.E., Cervantes, F., Champlin, R.E., Gale, R.P., Halter, J., Keating, A., Marks, D.I., McCarthy, P.L., Olavarria, E., Stadtmauer, E.A., Abecasis, M., Gupta, V., Khoury, H.J., G

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies.
Bartlett, N.L., Younes, A., Carabasi, M.H., Forero, A., Rosenblatt, J.D., Leonard, J.P., Bernstein, S.H., Bociek, R.G., Lorenz, J.M., Hart, B.W., Barton, J.

See all 22 publications

Insurances Accepted

  • Aetna Choice POS II
  • Aetna HMO
  • Anthem PPO
  • BCBS Blue Card PPO
  • CIGNA Open Access
  • Cofinity PPO
  • First Choice
  • First Health PPO
  • Great West PPO
  • HIP of New York - Select PPO
  • Horizon BCBS Direct Access
  • Horizon BCBS HMO
  • Horizon BCBS POS
  • Horizon BCBS PPO
  • Humana ChoiceCare Network PPO
  • Multiplan PHCS PPO
  • Multiplan PPO
  • Oxford Health Freedom
  • Oxford Health Liberty
  • Premera BCBS Heritage & Heritage Plus 1
  • Providence Health System Personal Option
  • QualCare HMO
  • QualCare PPO
  • Rocky Mountain Group/Indiv - HMO/Private Pay
  • United Healthcare - Direct Choice Plus POS
  • United Healthcare - Direct Options PPO
Find More Doctors
Doctor Finder

Our Doctor Finder includes most U.S. physicians. Doctors are not ranked, learn more.

Browse Doctors by



Search all Doctors

Profiles by Doximity

Your Message Has Been Submitted

As part of our research on the correction you submitted, you may be contacted at the email address provided.

Sorry, Your Message Could Not Be Submitted

Please try again later, or E-mail your message to doctors@usnews.com and include the Web address (URL) of the page that contains incorrect information.